"2 prizes for Incit at the Go Immuno congress - December 11 & 12, 2023".
INCIT in the spotlight at the "Go Immuno" conference organized by Labex IGO in December. In...
Publication date: July 28, 2022
Read also:
read more
European funding for immunotherapy of inflammatory bowel diseases
HORIZON Europe Framework Program : coordinated by F. ALTARE INCIT joins the RAISE network...
"Enterotoxigenic bacteria, biofilms and colorectal cancer immunotherapy".
Seminar Speaker: Franck Housseau (Johns Hopkins University) Location: May 28, 14.00 - Rooms 1, 2,...
"When Antibiotics Fail: Understanding Bacterial Persistence During Infection".
Seminar Speaker: Charlotte Michaux (U1230 - Rennes) Location: April 23, 11.00 - Rooms 1, 2, 3 -...
Read more articles
"2 prizes for Incit at the Go Immuno congress - December 11 & 12, 2023".
INCIT was honored at the "Go Immuno" conference organized by Labex IGO in December. Margaux Verdon (team 1) was awarded the prize for best poster, while Gwenann Cadiou (team 3) won the prize for best oral communication!
European funding for immunotherapy of inflammatory bowel diseases
The INCIT unit is pleased to announce that it has been awarded an ambitious European program on immunotherapy, bringing together 7 partners (including 2 biotechs) in 4 European countries. This program is coordinated by Frédéric ALTARE, Director of the UMR 1302, INCIT in Nantes. Project title: immunotherapy of inflammatory bowel diseases
"Enterotoxigenic bacteria, biofilms and colorectal cancer immunotherapy".
F. Altare's team has invited Prof. Franck Housseau (Johns Hopkins University) on May 28, 14.00. Seminar title: Enterotoxigenic bacteria, biofilms and colorectal cancer immunotherapy.
"When Antibiotics Fail: Understanding Bacterial Persistence During Infection".
The Angevine team has invited Charlotte Michaux from U1230 to Rennes on April 23 at 11.00. Title of her seminar: When Antibiotics Fail: Understanding Bacterial Persistence During Infection.
ReNAissance: revolutionizing antiviral treatments with messenger RNA
ReNAissance is one of the projects selected by the Impact Santé program, an initiative led by Inserm as part of France 2030. The aim of this program is to support the most daring, high-impact health research, by funding projects that push back the boundaries of current science and medicine.